VIRGINIA RETIREMENT SYSTEMS ET Al Buys 33,946 Shares of IDEXX Laboratories, Inc. $IDXX

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 36.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 126,164 shares of the company’s stock after buying an additional 33,946 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.16% of IDEXX Laboratories worth $65,882,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Crystal Rock Capital Management lifted its position in shares of IDEXX Laboratories by 6.4% in the 3rd quarter. Crystal Rock Capital Management now owns 11,275 shares of the company’s stock valued at $5,888,000 after acquiring an additional 675 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in IDEXX Laboratories by 10.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,015 shares of the company’s stock worth $1,608,000 after purchasing an additional 280 shares in the last quarter. BOKF NA raised its stake in IDEXX Laboratories by 9.1% during the 3rd quarter. BOKF NA now owns 3,453 shares of the company’s stock valued at $1,803,000 after purchasing an additional 289 shares during the period. Motley Fool Asset Management LLC raised its stake in IDEXX Laboratories by 1.2% during the 3rd quarter. Motley Fool Asset Management LLC now owns 6,988 shares of the company’s stock valued at $3,649,000 after purchasing an additional 83 shares during the period. Finally, North Dakota State Investment Board raised its stake in IDEXX Laboratories by 2.2% during the 3rd quarter. North Dakota State Investment Board now owns 2,421 shares of the company’s stock valued at $1,264,000 after purchasing an additional 52 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $551.21 on Friday. The company’s 50 day moving average price is $534.27 and its 200 day moving average price is $574.09. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The company has a market capitalization of $43.42 billion, a PE ratio of 38.76 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the firm earned $3.50 EPS. The company’s revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.79% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on IDXX shares. The Goldman Sachs Group initiated coverage on IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 target price for the company. JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday, October 16th. KeyCorp started coverage on IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating on the stock. Citigroup increased their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Finally, Leerink Partners reduced their price objective on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Eight equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $721.67.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.